The U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg), marking the first FDA-approved ophthalmic bevacizumab developed specifically for treating wet age-related macular degeneration (nAMD), a leading cause of vision loss in older adults. This approval represents a significant milestone for patients and eye care providers seeking validated treatment options for this progressive eye disease.

What Is Wet Age-Related Macular Degeneration?

Wet age-related macular degeneration occurs when abnormal blood vessels grow beneath the macula, the central part of the retina responsible for sharp, detailed vision. These leaky vessels can cause fluid to accumulate and damage light-sensitive cells, leading to blurred or distorted central vision. Unlike dry macular degeneration, which progresses slowly, wet macular degeneration can cause rapid vision loss if left untreated, making timely intervention critical.

How Does the New Approval Change Treatment Options?

Bevacizumab is a monoclonal antibody that works by blocking vascular endothelial growth factor (VEGF), a protein that signals the body to form new blood vessels. By reducing abnormal vessel growth, bevacizumab helps slow vision loss and may even improve sight in some patients. What sets LYTENAVA apart is that it was developed and manufactured specifically for eye injection, with rigorous clinical evidence supporting its safety and effectiveness in the retina.

According to Outlook Therapeutics, the company behind the approval, "for the first time, retina specialists and patients have access to an FDA-approved ophthalmic bevacizumab developed specifically for the eye and supported by rigorous clinical evidence, validated manufacturing, approved labeling, comprehensive quality systems, and ongoing FDA regulatory oversight." The company expects to make LYTENAVA available to eligible patients in the United States by the end of 2026.

What Should Patients Know About Access and Timeline?

The commercial launch is underway, and eligible patients should be able to access LYTENAVA through their retina specialists within the coming months. Patients with wet age-related macular degeneration who have not responded adequately to other treatments, or those newly diagnosed, should discuss this option with their eye care provider. The approval process included comprehensive quality systems and ongoing FDA regulatory oversight, ensuring consistent manufacturing standards and patient safety.

Steps to Take If You Have Age-Related Macular Degeneration

• Schedule Regular Eye Exams: Early detection of wet macular degeneration is crucial; adults over 50 should have comprehensive dilated eye exams at least annually, especially if they have risk factors like family history or smoking history.
• Monitor Your Vision: Use the Amsler grid test at home to check for sudden changes in central vision, such as wavy lines, blurred spots, or dark areas; report any changes to your eye doctor immediately.
• Discuss Treatment Options: If diagnosed with wet macular degeneration, ask your retina specialist about all available treatments, including LYTENAVA, to determine which option is best for your specific condition and medical history.

Why This Approval Matters for Eye Health

The approval of LYTENAVA expands the toolkit available to retina specialists treating wet age-related macular degeneration. Having an FDA-approved bevacizumab formulation developed specifically for ophthalmic use provides physicians with a validated option backed by rigorous clinical evidence and comprehensive quality oversight. This can improve treatment consistency and patient outcomes across different clinical settings. For patients, it means more choices and potentially better access to proven therapies that can help preserve vision during the critical early stages of wet macular degeneration.

Age-related macular degeneration remains one of the leading causes of vision loss in people over 50 in developed countries. With an aging population, the demand for effective treatments continues to grow. The availability of LYTENAVA represents progress in addressing this significant public health challenge and offers hope to millions of people at risk for or living with this condition.